Myriad Genetics Promotes 63-Gene MyRisk Cancer Test with Jackie Tohn Partnership
Myriad Genetics partnered with actress Jackie Tohn after her BRCA1 discovery—she faced 85% breast and 65% ovarian cancer risk and elected prophylactic surgeries. MyRisk screens 63 genes across 11 cancers and uses RiskScore to deliver breast cancer predictions twice as predictive as history alone.
1. Campaign and Patient Story
Myriad Genetics has teamed up with actress Jackie Tohn to spotlight hereditary cancer testing after she discovered a BRCA1 variant. Following her father’s diagnosis and her own 85% breast and 65% ovarian cancer risk, Tohn opted for a prophylactic double mastectomy and planned oophorectomy.
2. MyRisk Test Features and Performance
The MyRisk Hereditary Cancer Test evaluates 63 genes associated with 11 cancer types and combines personal history, family history and roughly 150 genetic markers to generate a RiskScore. This personalized assessment delivers breast cancer risk predictions that are twice as predictive as history-based evaluations alone.
3. Market Reach and Clinical Integration
Myriad Genetics pioneered BRCA gene sequencing over 30 years ago and has tested more than 3 million patients. The MyRisk test is available through healthcare providers or virtual care with results in 14 days, and board-certified genetic counselors offer complimentary consultations to guide patient decisions.